Current Management and Controversies Surrounding Andropause.
Andropause
Hypogonadism
TRT
Testosterone
Journal
The Urologic clinics of North America
ISSN: 1558-318X
Titre abrégé: Urol Clin North Am
Pays: United States
ID NLM: 0423221
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
entrez:
29
10
2022
pubmed:
30
10
2022
medline:
2
11
2022
Statut:
ppublish
Résumé
Andropause is a condition surrounded by controversies, whether it be through its diagnosis or management. As we learn more about the pathophysiology of hypogonadism, our perspectives on the risks and benefits of testosterone therapy have shifted. We attempt to discuss the most modern and relevant points of controversy currently affecting the field. Throughout this review, we discuss the art of diagnosing hypogonadism as well as the association or lack thereof between testosterone replacement therapy and cardiovascular disease, prostate cancer, thrombosis, antiaging effects, exogenous steroid abuse, and diabetes mellitus.
Identifiants
pubmed: 36309415
pii: S0094-0143(22)00050-7
doi: 10.1016/j.ucl.2022.07.003
pii:
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-592Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.